Department of Cardiology, Tokai University School of Medicine.
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine.
Circ J. 2021 May 25;85(6):939-943. doi: 10.1253/circj.CJ-21-0087. Epub 2021 Apr 29.
Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).
In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.
This study suggests the potential benefits of statins use against COVID-19.
心血管疾病和/或危险因素（CVDRF）已被报道为严重的 2019 年冠状病毒病（COVID-19）的危险因素。
我们从日本的 CLAVIS-COVID 数据库中总共选择了 693 例有 CVDRF 的患者，共 1518 例。平均年龄为 68 岁（35%为女性）。入院时报告有 31%的患者使用他汀类药物。尽管他汀类药物使用者有更多的合并症，如糖尿病，但他汀类药物使用者的体外膜氧合（ECMO）插入（1.4%比 4.6%，比值比[OR]：0.295，P=0.037）和感染性休克（1.4%比 6.5%，OR：0.205，P=0.004）发生率较低。
本研究提示他汀类药物可能对 COVID-19 有潜在益处。
Zotero 插件